KR20070112546A - Food composition comprising extracts from lycium chinenses mill - Google Patents
Food composition comprising extracts from lycium chinenses mill Download PDFInfo
- Publication number
- KR20070112546A KR20070112546A KR1020060045576A KR20060045576A KR20070112546A KR 20070112546 A KR20070112546 A KR 20070112546A KR 1020060045576 A KR1020060045576 A KR 1020060045576A KR 20060045576 A KR20060045576 A KR 20060045576A KR 20070112546 A KR20070112546 A KR 20070112546A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- goji
- food composition
- wolfberry
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims abstract description 16
- 235000013305 food Nutrition 0.000 title claims abstract description 11
- 244000241872 Lycium chinense Species 0.000 title abstract description 47
- 235000015468 Lycium chinense Nutrition 0.000 title abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 6
- 239000012153 distilled water Substances 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000004108 freeze drying Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 208000001132 Osteoporosis Diseases 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 230000002611 ovarian Effects 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 102000004067 Osteocalcin Human genes 0.000 description 6
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000020687 goji berry extract Nutrition 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000008866 Ziziphus nummularia Species 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 235000007173 Abies balsamea Nutrition 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 239000004857 Balsam Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 244000018716 Impatiens biflora Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101000983304 Rattus norvegicus Osteocalcin Proteins 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010046764 Uterine atrophy Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- -1 oral preparations Substances 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 231100001042 uterine atrophy Toxicity 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- ZBQCCTCQUCOXBO-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine Chemical compound CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 ZBQCCTCQUCOXBO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 108010021337 lipoprotein triglyceride Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 쥐에서의 체중 변화를 나타내는 그라프도.1 is a graph showing weight changes in rats.
도 2는 난소적출한 쥐에서의 자궁 체중에 미치는 LCF 및 LCL의 효과를 나타내는 그라프도.2 is a graph showing the effect of LCF and LCL on uterine body weight in ovarian isolated mice.
도 3은 시험 모델의 자궁의 횡단면 사진.3 is a cross-sectional picture of the uterus of the test model.
도 4는 자궁적출한 쥐에서 혈청 오스테오칼신에 미치는 LCF 및 LCL의 효과를 나타내는 도면.4 shows the effect of LCF and LCL on serum osteocalcin in uterine isolated mice.
도 5는 자궁적출한 쥐에서의 알칼린 포스포타아제 활성에 미치는 LCF 및 LCL의 효과를 나타내는 그라프도.5 is a graph showing the effect of LCF and LCL on alkaline phosphatase activity in uterine isolated mice.
도 6은 각 시험 모델의 주사전자 현미경 사진.6 is a scanning electron micrograph of each test model.
도 7은 각 시험 모델의 조직학적 변화를 나타내는 사진.7 is a photograph showing the histological changes of each test model.
본 발명은 구기자 추출물을 포함하는 조성물에 관한 것으로, 더욱 구체적으로는 구기자 추출물을 포함하는 조성물의 용도에 관한 것이다. 본 발명의 구기자 추출물은 천연물에서 유래한 것으로 부작용이 없으며 고지혈증, 고콜레스테롤증을 현저하게 개선하므로 관련 질환의 치료용 식품 성분으로 이용할 수 있다.The present invention relates to a composition comprising a wolfberry extract, and more particularly to the use of a composition comprising a wolfberry extract. Goji berry extract of the present invention is derived from a natural product has no side effects and significantly improves hyperlipidemia, hypercholesterolemia can be used as a food ingredient for the treatment of related diseases.
구기자는 가지과에 속하는 구기자 나무의 열매로서, 고유의 미감(味感)을 지니며 카로틴, 비타민 B1, B2, 및 C, 니코틴산, 리놀산, 베타인, 피잘리엔 및 β-시스토스테롤(β-sistosterol)과 각종 무기성분 등을 다량 함유하고 있어 강장, 성인병예방과 치료, 시력보호, 피부미용, 정신집중력향상, 청혈작용 등의 효능이 인정되고 있으며, 한방의 필수약제로 오랜 세월 사용되어 왔을 뿐만 아니라 현대 의학계에 있어서는 드링크제 원료의 첨가제로 널리 쓰이고 있으며, 특히, 음주가들이 복용하는 경우 지방간이 형성되는 것을 방지한다는 것이 밝혀진 바 있다. Goji is a fruit of the Goji berry family belonging to the branch family, has a unique sense of taste and has carotene, vitamin B 1 , B 2 , and C, nicotinic acid, linoleic acid, betaine, pisaliene and β-cystosterol ( It contains a large amount of β-sistosterol) and various inorganic ingredients, and it has been recognized for its efficacy in tonic, adult disease prevention and treatment, eyesight protection, skin care, mental concentration improvement, and blue blood effect, and has been used as an essential medicine for many years. In addition, it is widely used as an additive of a drink material in modern medicine, and it has been found to prevent fatty liver formation, especially when drinkers take it.
구기자는 한국각지에서 재배 가능하나 기온이 따뜻한 진도에서 생산된 것이 그 맛과 향이 깊은 것으로 판명되고 있다. Goji berries can be cultivated in various parts of Korea, but it is found to have a deep taste and aroma produced in Jindo, where the temperature is warm.
이와 같이 여러 가지 효능이 있는 것으로 알려진 구기자에 대하여 지금까지는 주로 오미자, 영지, 대추 등의 여러 가지 다른 생약재와의 혼합물 형태로서 주로 차나 음료 및 증류주 형태의 주류로서 제조되어 왔다. As such, goji berries known to have various effects have been produced mainly as a mixture of various herbal medicines such as schisandra chinensis, ganoderma lucidum and jujube, mainly as teas, beverages and liquor.
종래 구기자를 이용한 차 또는 기타 음료의 제법에 관한 특허 공고 문헌으로는, 특허공고 제91-6938호 "구기자 음료의 제조 방법"에 관한 것으로, 구기자, 오미자, 영지, 대추 등의 원료를 물에 함께 넣어 가열하여 농축시킨 다음, 정제수와 함께 꿀, 설탕, 과당, 구연산, 구연산소다, 솔비톨 분말, 비타민C 등의 첨가물을 복합토록 한 것으로, 순수한 구기자 음료가 아니라 구기자가 포함된 복합 한방재료 를 이용한 음료의 제조 방법을 볼 수 있다. Patent publication related to the manufacturing method of tea or other beverages using conventional wolfberry relates to Patent Publication No. 91-6938, "Method of manufacturing a wolfberry drink," which contains raw materials such as wolfberry, schisandra chinensis, jujube and jujube in water After condensation by heating, the mixture of honey, sugar, fructose, citric acid, sodium citrate, sorbitol powder, vitamin C, etc. together with purified water is used. The manufacturing method of can be seen.
이와 같은 종래 특허문헌은 구기자를 이용한 음료 및 주정음료에 관한 것을 볼 수 있으나, 이들은 모두 순수한 구기자만을 이용한 것이 아니라 구기자와 기타 한방재료들을 복합하여 제조토록 하는 구기자가 포함된 복합 음료에 관한 것임을 알 수 있다. Such a conventional patent document can be seen that related to beverages and alcoholic beverages using goji, but all these are related to a complex drink containing gojija to produce a mixture of goji and other herbal ingredients, not just pure gojija have.
그러나, 구기자를 포함한 복합음료의 제조방법이 아닌 구기자 단독의 성분을 이용하여 제형화한 시도는 거의 없다.However, few attempts have been made to formulate the ingredients of wolfberry alone, rather than a method for producing a complex beverage including wolfberry.
본 발명자들은 천연물로부터 건강에 유익한 성분들을 찾고자 구기자를 대상으로 예의 연구를 거듭한 결과, 후술하는 바와 같이 추출한 구기자의 열매 및 잎의 성분이 특히, 갱년기의 여성의 혈중 지질성분을 효과적으로 감소시킬 수 있음을 확인하고 본 발명을 완성하기에 이르렀다.The present inventors have conducted intensive studies on goji berries to find ingredients beneficial to health from natural products, and as described below, the extracts of goji berries and leaves of goji berries can effectively reduce blood lipid components of menopausal women. It was confirmed to complete the present invention.
따라서, 본 발명의 목적은 구기자의 열매 및 잎으로부터의 열수 추출물을 포함하는 고지혈증, 고콜레스테롤증의 개선용 의약 및 식품 조성물을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a pharmaceutical and food composition for improving hyperlipidemia, hypercholesterolemia, including hot water extracts from the fruits and leaves of wolfberry.
본 발명의 추가의 목적 및 이점은 이후의 명세서의 기재 사항으로부터 명백할 것이다.Further objects and advantages of the invention will be apparent from the description in the following specification.
본 발명은 구기자의 열매 및 잎으로부터의 열수 추출물을 포함하는 고지혈증, 고콜레스테롤증의 개선용 의약 및 식품 조성물을 제공한다.The present invention provides a medicament and food composition for improving hyperlipidemia, hypercholesterolemia, including hydrothermal extracts from the fruits and leaves of wolfberry.
본 발명에 따르는 조성물은 약제학적 분야에서 통상적인 방법에 의해 제조할 수 있다. 구체적으로, 건조 구기자와 음건한 구기자 잎 200-250g을 증류수 3 리터를 가하여 약탕기로 약 100 ℃의 온도에서 2시간 30분 정도 전탕하여 감압 농축시킨 후 추출액을 여과 및 동결건조하여 파우다를 얻고 이를 필요에 따라 희석하여 사용할 수 있다.The composition according to the invention can be prepared by methods conventional in the pharmaceutical art. Specifically, 200-250 g of dried wolfberry and dry wolfberry leaves were added with 3 liters of distilled water, and the mixture was concentrated under reduced pressure for 2 hours and 30 minutes at a temperature of about 100 ° C. with a water bath, and the extract was filtered and lyophilized to obtain powder. It can be diluted according to use.
본 발명의 제약 및 식품 조성물은 특히 갱년기의 여성의 고지혈증 및 고콜레스테롤증의 개선에 가장 적합하게 사용될 수 있으며, 당업자는 그러한 질병, 상태 및 이상으로부터 고통을 받는 것으로 추정되는 개인들을 표준 진단 기술을 사용하여 용이하게 파악할 수 있다. The pharmaceutical and food compositions of the present invention may be best suited for the improvement of hyperlipidemia and hypercholesterolemia, especially in menopausal women, and those skilled in the art use standard diagnostic techniques for individuals suspected of suffering from such diseases, conditions and abnormalities. Can be easily grasped.
본 발명의 제약 조성물은 공지의 의약용 담체와 조합하여 제제화할 수 있다. 일반적으로는, 유효 성분을 약학적으로 허용할 수 있는 액상 또는 고체상의 담체와 배합하고, 또한 필요에 따라 용제, 분산제, 유화제, 완충제, 안정제, 부형제, 결합제, 붕괴제, 활택제 등를 가하고, 정제, 과립제, 산제, 분말제, 캡슐제 등의 고형제, 통상액제, 현탁제, 유제 등의 액제로 할 수 있다. 또한 이것을 사용 전에 적당한 담체의 첨가에 의해 액상으로 만들 수 있는 건조품으로 할 수도 있다.The pharmaceutical composition of the present invention can be formulated in combination with a known medical carrier. Generally, the active ingredient is combined with a pharmaceutically acceptable liquid or solid carrier, and a solvent, a dispersant, an emulsifier, a buffer, a stabilizer, an excipient, a binder, a disintegrant, a lubricant, and the like are added as needed, and the tablet is purified. And solid solutions such as granules, powders, powders, and capsules, liquids such as ordinary liquids, suspensions, and emulsions. Moreover, it can also be set as the dry product which can be made into a liquid state by addition of a suitable carrier before use.
본 발명의 제약 조성물은 경구제나, 주사제, 점적용제 등의 비경구제 중의 어떠한 것에 의해서도 투여할 수 있다.The pharmaceutical composition of the present invention can be administered by any of parenteral agents such as oral preparations, injections, and drops.
의약용 담체는 상기 투여형태 및 제형에 따라서 선택할 수 있고, 경구제의 경우는, 예를 들어 전분, 유당, 백당, 만니톨, 카복시메틸셀룰로스, 콘 스타치, 무기염 등이 이용된다. 또한 경구제의 조제에 있어서는 추가로 결합제, 붕괴제, 계면 활성제, 윤택제, 유동성 촉진제, 교미제, 착색제, 향료 등을 배합할 수도 있다.A medical carrier can be selected according to the said dosage form and formulation, and, in the case of an oral preparation, starch, lactose, white sugar, mannitol, carboxymethylcellulose, corn starch, an inorganic salt, etc. are used, for example. Moreover, in preparation of an oral preparation, you may mix | blend a binder, a disintegrating agent, surfactant, a lubricating agent, a fluidity promoter, a copper, a coloring agent, a fragrance | flavor, etc. further.
한편, 비경구제의 경우는 통상의 방법에 따라서 본 발명의 유효성분인 단백분해효소를 포함하는 조성물을 희석제로서의 주사용 증류수, 생리식염수, 포도당 수용액, 주사용 식물유, 참기름, 낙화생유, 대두유, 옥수수유, 프로필렌글리콜, 폴리에틸렌글리콜 등에 용해 내지 현탁시켜서 필요에 따라 살균제, 안정제, 등장화제, 무통화제 등을 가함으로써 조제된다.On the other hand, in the case of parenterals, distilled water for injection as a diluent, saline solution, glucose aqueous solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn according to a conventional method It is melt | dissolved or suspended in oil, propylene glycol, polyethyleneglycol, etc., and it is prepared by adding a disinfectant, a stabilizer, an isotonicity agent, a non-fatting agent etc. as needed.
본 발명의 의약 조성물은 제제 형태에 따른 적당한 투여경로로 투여된다. 투여방법은 특히 한정할 필요는 없고, 내용, 외용 및 주사에 의해 투여할 수 있다. 주사제는, 예를 들어 정맥내, 근육내, 피하, 피내 등에 투여할 수 있다.The pharmaceutical composition of the present invention is administered by a suitable route of administration according to the formulation form. The administration method need not be particularly limited and can be administered by internal content, external application, and injection. Injections can be administered, for example, intravenously, intramuscularly, subcutaneously, intradermally or the like.
본 발명의 제약 조성물의 투여량은, 그 제제형태, 투여방법, 사용 목적 및 이것에 적용되는 환자의 연령, 체중, 증상에 따라서 적절히 설정되고, 일정하지 않지만 일반적으로는 제제 중에 함유되는 유효성분의 양은 성인 1일당 예컨대 0.1- 40 ㎎/㎏이며, 하루 1-6회 투여될 수 있다. 그러나, 당업자는 특정 시약의 약물동력학적인 특성 및 그의 투여 모드 및 경로; 수여자의 나이, 건강, 체중; 증상의 성질 및 정도, 동시 치료의 종류, 치료의 빈도 및 목적하는 효과 등의 공지의 요인에 따라서 투여량이 변화함은 이해할 것이다. The dosage of the pharmaceutical composition of the present invention is appropriately set in accordance with the form of the preparation, the method of administration, the purpose of use, and the age, weight, and symptoms of the patient to be applied thereto, but is not constant but generally used in the preparation of the active ingredient. The amount is, for example, 0.1-40 mg / kg per adult, and may be administered 1-6 times a day. However, those skilled in the art will appreciate the pharmacokinetic properties of certain reagents and their mode and route of administration; Age, health and weight of the recipient; It will be appreciated that the dosage will vary depending on known factors such as the nature and extent of the symptoms, the type of concurrent treatment, the frequency of treatment and the desired effect.
본 발명의 조성물은 또한 혈중 지질농도를 저하시키는 작용에 의해 건강 기능성 식품 조성물로서 사용될 수 있다. The composition of the present invention can also be used as a health functional food composition by the action of lowering blood lipid concentration.
본 발명에 따른 기능성 식품 조성물의 제형은 당해 분야에서의 통상적인 방법에 따라, 예를 들면 경구제, 파우치제, 또는 드링크제 등의 음료수의 형태로 제 형화시켜 사용할 수 있다.The formulation of the functional food composition according to the present invention can be formulated in the form of a beverage, such as, for example, oral, pouch, or drink, according to conventional methods in the art.
본 발명의 식품 조성물의 복용량은, 그 제제 형태, 투여 방법, 사용 목적 및 이것에 적용되는 환자의 연령, 체중, 증상에 따라서 적절히 설정되고, 일정하지 않지만 일반적으로는 제제 중에 함유되는 유효성분의 양은 성인 1일당 예컨대 0.1 내지 40 ㎎/㎏이며, 바람직하기로는 0.4 내지 40 ㎎/㎏ 이다. 물론 복용량은, 각종 조건에 의해서 변동하기 때문에, 상기 투여량보다 적은 양으로 충분한 경우도 있고, 또는 범위를 초과하여 필요한 경우도 있다.The dosage of the food composition of the present invention is appropriately set according to the form of the preparation, the method of administration, the purpose of use, and the age, weight, and symptoms of the patient to be applied thereto, but the amount of the active ingredient contained in the preparation is generally not constant. Such as 0.1 to 40 mg / kg per adult, preferably 0.4 to 40 mg / kg. Of course, since the dose varies depending on various conditions, an amount smaller than the dose may be sufficient, or it may be necessary beyond the range.
본 발명에 따른 식품 조성물은 원하는 조성물의 형태에 따라 통상의 보조제 또는 첨가제, 또는 감미료, 예를 들면 감초, 비타민 C, 구연산, 니코틴산, 안식향산나트륨, 아스파탐, 사카린, 펙틴, 말리톨, 솔비톨, 자일리톨, 구아검, 탈지분유 및 올리고당으로 이루어진 군 중에서 선택되는 하나 이상의 성분을 추가하여 기호도나 미감을 증대시킬 수 있다.The food composition according to the present invention may be prepared according to the form of the composition desired by conventional supplements or additives or sweeteners such as licorice, vitamin C, citric acid, nicotinic acid, sodium benzoate, aspartame, saccharin, pectin, malitol, sorbitol, xylitol, One or more ingredients selected from the group consisting of guar gum, skim milk powder, and oligosaccharides can be added to increase palatability or aesthetics.
이들은 본 발명의 조성물의 전체 중량을 기준으로 약 0.01~20 중량%로 사용하는 것이 적절하다.They are suitably used at about 0.01 to 20% by weight based on the total weight of the composition of the present invention.
음료수는, 예를 들면, 상기 구기자 추출물을 0.01~20 중량%으로 넣고, 감초 0.01~2 중량%, 구연산을 0.01~2 중량%, 사과산 0.01~2 중량%, 타우린 0.1∼2 중량%, 비타민 C 0.01~2 중량%, 비타민 B1 0.01~2 중량%, 바이오틴 0.01~2 중량%, 액상과당 0.01~2 중량% 등을 단독 또는 혼합하여 첨가하여 기능성 음료수로 제조할 수 있다.Drinking water, for example, put the wolfberry extract in 0.01 to 20% by weight, licorice 0.01-2% by weight, citric acid 0.01-2% by weight, malic acid 0.01-2% by weight, taurine 0.1-2% by weight, vitamin C 0.01-2% by weight, 0.01-2% by weight of vitamin B1, 0.01-2% by weight of biotin, 0.01-2% by weight of liquid fructose, or the like can be added alone or mixed to prepare a functional beverage.
<실시예><Example>
이하, 본 발명을 실시예에 의해 더욱 구체적으로 설명한다. 그러나 이들은 단지 예시적인 것이며, 본원 발명을 이들에 한정하고자 의도한 것은 아니다. 본 발명의 실시예 및 실험예의 데이터에 있어서 각군별 실험성적은 평균표준편차로 나타내었다. 각 측정치의 통계처리는 정상대조군 값에 대비한 각 시료군의 값을 unpaired t-test를 이용하여 검정하였으며 P값이 0.05이하인 경우 유의한 차이가 있는 것으로 간주하였다. Hereinafter, the present invention will be described in more detail with reference to Examples. However, these are merely exemplary and are not intended to limit the present invention to them. In the data of Examples and Experimental Examples of the present invention, the experimental results for each group are expressed as the average standard deviation. Statistical analysis of each measurement was performed by using an unpaired t-test for each sample group compared to the normal control group, and it was considered that there was a significant difference when the P value was less than 0.05.
실시예Example 1: 구기자와 1: wolfberry and 구기잎의Goji leaf 분말 및 추출액 정제 Powder and Extract Tablets
본 실시예에서 사용한 구기자와 구기잎은 전남 진도군 진도구기자유통영농조합에서 2005년도에 친환경유기농법으로 생산된 것을 제공받아 사용하였다. 건조 구기자 200 g과 음건한 구기자 잎 250 g을 증류수 3 ℓ를 가하여 대웅약탕기(DWP-9900T, 한국)로 약 100℃의 온도에서 2시간 30분 동안 전탕하여 감압 농축시킨 후 추출액 1 ℓ를 부직포와 Whattman paper No.1 으로 여과하고 동결 건조기(SFDSM06, 삼원, 한국)를 이용하여 동결 건조 후 파우더로 건조 추출물 100 g을 얻었다. 이 파우더는 증류수로 희석하여 별도의 언급이 없는 한 후속 실시예 및 시험예에 사용하였다. 후속 시험예에서는 효과 검증을 위해 각 동물실험군에 음용수로 섭취하도록 건조 분말을 증류수로 희석하여 100 mg/kg 매일 투여하였다. Goji berries and goji leaves used in this embodiment was used by Jindo-gun Jindogi Free Trade Farming Association Jeonnam produced by the environment-friendly organic farming method in 2005. 200 g of dried wolfberry and 250 g of dry wolfberry leaves were added with 3 L of distilled water, and then concentrated by distillation under reduced pressure for 2 hours and 30 minutes at a temperature of about 100 ° C with Daewoong tangtang (DWP-9900T, South Korea). After filtering with Whattman paper No. 1 and freeze drying using a freeze dryer (SFDSM06, Samwon, Korea) to obtain a dry extract 100g as a powder. This powder was diluted with distilled water and used in the subsequent examples and test examples unless otherwise noted. In subsequent test examples, the dry powder was diluted with distilled water to be administered as drinking water to each animal test group to verify the effect, and 100 mg / kg was administered daily.
실시예 2: 기능성 구기자 파우치 제품의 제조Example 2: Preparation of Functional Wolfberry Pouch Products
실시예 1의 구기자 추출물 100g에 감초 1g, 구연산 20g, 아스파탐 17 g 및 비타민 C 30 g을 첨가한 후 나머지를 정제수로 첨가하여 음료수 2 ℓ를 제조하여 이를 통상의 방식으로 진공포장하여 파우치를 제조하였다. 결과적으로 본 발명 음 료수는 종래의 음료수 제품과 입안 감촉, 맛 그리고 종합평가 면에서 양호한 반응을 얻었다.1 g of licorice, 20 g of citric acid, 17 g of aspartame and 30 g of vitamin C were added to 100 g of Goji berry extract of Example 1, and the rest was added to purified water to prepare 2 l of drinking water and vacuum-packed in a conventional manner to prepare a pouch. . As a result, the beverage of the present invention obtained a favorable response in terms of mouth feel, taste, and comprehensive evaluation with conventional beverage products.
실시예 3: 제약학적 제제Example 3: Pharmaceutical Formulations
제형의 형태(정제)Form of Formulation (Tablet)
본 발명 구기자 추출물 80 mg80 mg of wolfberry extract of the present invention
락토오스 50 mgLactose 50 mg
전분 20 mgStarch 20 mg
스테아르산 마그네슘 5 mg5 mg magnesium stearate
결정성 셀룰로오스 15 mg15 mg of crystalline cellulose
본 발명의 한 실시 형태는 그 예를 상기에 나타낸 정제의 유효 성분으로써 상기 구기자 추출물의 용도이다. 정제는 통상의 방법에 의해 제조될 수 있으며, 한 바람직한 실시형태는 통상의 장용성 피복(예를 들면, 히드록시프로필메틸 셀룰로오스 프탈레이트), 당코팅 또는 피막 코팅을 갖는 정제 또는 연질캅셀 형태이다.One embodiment of the present invention is the use of said wolfberry extract as an active ingredient of the tablet shown above. Tablets may be prepared by conventional methods, and one preferred embodiment is in the form of tablets or soft capsules with conventional enteric coatings (eg hydroxypropylmethyl cellulose phthalate), sugar coatings or film coatings.
시험예 1: 실험군 설정 및 시험 모델의 유도Test Example 1 Experimental Set Up and Derivation of Test Model
구기자와 구기잎의 골다공증예방효과에 관한 실험군은 정상군으로 난소적출하지 않고 하복부의 피부와 복막 절개 후 봉합한 가장수술군(Sham), 난소적출한 골다공증군(OVX), 난소적출 후 구기자 투여군(LCF)과 구기자잎 투여군(LCL), 골다공증 예방 및 치료제인 에스트로겐 투여군(E2)의 5개군으로 분류하였다.The experimental group on the osteoporosis prevention effect of goji and goji leaves was normal group. LCF), Goji berry leaves (LCL), and estrogen-treated group (E 2 ), an osteoporosis prevention and treatment, were divided into five groups.
생후 9주령의 스프라그-다우리(Sprague-Dawley) 흰쥐로부터 무균 조작 하에 양측 난소 적출술을 시행하였다. 일반적인 수술 전 처치방법에 따라 10% 포비돈 요오드로 수술부위 및 주위를 소독한 후, 무균 조작 하에서 하복부의 피부, 근육, 복막의 절개를 시행하여 양쪽 난소를 모두 노출시킨 후 난소를 절개하고 절제부위는 결찰 및 봉합하였다. 골다공증 예방효과를 관찰하기위해 난소 적출 후부터 8주 동안 구기자와 구기잎을 음용수로 매일 투여하였다. 가장 수술군에 대해서는 복막 절개까지만 같은 방법으로 시행하고, 난소를 적출하지 않은 채로 다시 봉합하여 정상군으로 음용수로 물을 투여하였다. Bilateral ovarian extraction was performed under aseptic manipulation from 9 week-old Sprague-Dawley rats. Sterilize the surgical site and the surrounding area with 10% povidone iodine according to the usual preoperative procedures, and excision of both ovaries by excision of the skin, muscle, and peritoneum of the lower abdomen under aseptic manipulation, exposing both ovaries and excision Ligation and sutures. To observe the prevention of osteoporosis, goji and goji leaf were administered daily as drinking water for 8 weeks after ovarian extraction. In the most surgical group, peritoneal incision was performed in the same way, and the suture was resealed without extraction of the ovaries and water was administered to the normal group as drinking water.
시험예 2: 에스트로겐 호르몬 치료주사 및 체중 변화 시험Test Example 2: Estrogen Hormone Injection and Weight Change Test
자궁은 모두 에스트로겐에 의존적이며, 난소에서만 분비되므로 난소가 제거되면 자궁 위축 현상이 일어나며 골소실이 현저히 증가된다. 골다공증의 원인중 하나는 에스트로겐의 결핍이다. 본 실험예에서는 호르몬 치료요법으로 에스트로겐 투여군에는 난소적출술을 행하고 난 다음날부터 체중 100 g당 에스트로겐 0.001 mg을 1일 1회 8주간 주사하였다. The uterus is all estrogen dependent and secreted only from the ovary, so when the ovary is removed, uterine atrophy occurs and bone loss is significantly increased. One cause of osteoporosis is a lack of estrogen. In this experimental example, 0.001 mg of estrogen per 100 g of body weight was injected once a day for 8 weeks from the day after ovarian extraction to the estrogen-administered group as a hormonal therapy.
체중 220±5 g의 9주령 흰쥐를 대전광역시 소재의 다물사이언스㈜로부터 구입하여 동신대학교 한의과대학 사육실에서 정상적인 사육환경에 1주 동안 적응시킨 후 수술 직전과 수술 후 2주, 4주, 6주, 8주 되는 날의 체중을 측정하여 그 변화를 관찰하였다. 실험에 사용한 모든 흰쥐는 희생하기 전 12시간 동안 절식시킨 다음 관찰하였다. 정상군과 골다공증군은 일반 사료와 물을 제공하였으며 난소적출군에 구기자와 구기잎을 8주간 투여하고 그 결과를 표 1 및 도 1에 나타냈다. 도 1은 쥐에서의 체중 변화를 나타내는 그라프도이다. Sham: 가장 수술군, OVX: 난소적출골 다공증군, LCF, LCL 및 E2: 각 난소적출후, 구기자, 구기자 잎 및 에스트라디올을 투여한 군을 나타낸다. 각 포인트는 평균 ± SD(n=7)로 나타냈다.. Nine-week-old rats weighing 220 ± 5 g were purchased from Damul Science Co., Ltd., Daejeon Metropolitan City, and adapted to normal breeding environment for one week at the College of Oriental Medicine, Dongshin University. The body weight was measured at 8 weeks old and the change was observed. All rats used in the experiment were observed after fasting for 12 hours before sacrifice. The normal group and osteoporosis group provided general feed and water, and 8 hours of goji and goji leaves were administered to the ovarian extraction group and the results are shown in Table 1 and FIG. 1. 1 is a graph showing weight change in rats. Sham: The most surgical group, OVX: Ovarian osteoporosis group, LCF, LCL and E 2 : After each ovarian extraction, wolfberry, wolfberry leaf and estradiol group were administered. Each point is represented by mean ± SD (n = 7).
표 1 및 도 1의 결과에서 알 수 있듯이 8 주후 골다공증군의 체중은 330±5.4 g으로 현저하게 증가하였고 구기자와 구기자잎을 투여한 경우 각각 328±3 g, 322±2.5 g 약간 감소하였으나 통계적인 차이를 보이지 않았다. 본 실험에서도 흰쥐의 난소를 제거하면 성장속도가 증가하여 체중증가가 된다는 보고와 같은 결과를 보여주었으며 이중 구기자와 구기자잎을 투여한 군에서는 난소만 절제한 군에 비해 체중증가율은 낮았다. As can be seen from the results of Table 1 and FIG. 1, the body weight of the osteoporosis group was significantly increased to 330 ± 5.4 g after 8 weeks, and decreased slightly by 328 ± 3 g and 322 ± 2.5 g, respectively. There was no difference. In the present experiment, the removal of the ovaries of rats increased the growth rate and resulted in weight gain, and the weight gain rate was lower in the group treated with goji berry and goji leaf compared to the ovarian-only group.
시험예3: 자궁의 변화 및 조직학적 관찰Test Example 3: Changes in the Uterus and Histological Observation
흰쥐에서 난소 제거술이 성공적으로 되었는지를 알기 위하여 자궁무게와 자궁관의 조직학적 변화를 관찰했다. 그 결과를 도 2에 나타냈다. 도 2는 난소적출한(ovariectomized) 쥐에서의 자궁 체중에 미치는 LCF 및 LCL의 효과를 나타내는 그라프도이다. 각 포인트는 평균값±SD(n=7)으로 나타냈다. 도 2의 결과로부터 자궁 무게는 골다공증군 모두 현저히 감소하였으나 구기자잎을 투여한 군에서 약간의 증가가 있었으며 에스트로겐 투여군은 현저히 증가하였다. 자궁무게의 감소와 자궁위축 소견이 나타나 난소절제술이 성공적으로 이루어졌다는 점을 알 수 있었다. 도 3은 시험 모델의 자궁의 횡단면 사진이다. A: 가장 수술군, OVX: 난소적출골다공증 대조군 쥐, C, D 및 E: 각 난소적출후, 구기자, 구기자 잎 및 에스트라디올을 투여한 군을 나타낸다. 헤마톡시실린 및 에오신 염색 절편이다. 원본 배율 x 20으로 나타낸 사진이다. 도 3은 흰쥐의 자궁조직을 적출하여 4% 파라포름알데히드를 사용하여 24시간 고정시킨 다음 파라핀으로 포매한 후 마이크로톰으로 조직을 5 ㎛두께로 절편하였다. 절편한 조직을 슬라이드 글라스 위에 부착시킨 다음 이를 자일렌에서 파라핀을 제거하고 100%, 90%, 80% 에탄올과 같이 농도가 낮아지는 순으로 5분씩 담구어 함수과정을 거쳐, 흐르는 물에 10분간 세척하였다. 슬라이드 물기를 제거 하여 HE 염색을 한 후 카나다 발삼으로 마운트 하여 광학현미경으로 관찰, 사진 촬영하였다. 결과 자궁관의 직경은 정상군에 비하여 골다공증군과 구기자 투여군에서는 매우 위축되었으며, 구기자잎 투여군의 자궁직경은 골다공증군에 비해 다소 증가하였고, 에스트로겐의 직경은 정상군과 비슷하였다.To determine whether the ovarian removal was successful in the rat, the uterine weight and histological changes of the uterine tube were examined. The result is shown in FIG. 2 is a graph showing the effect of LCF and LCL on uterine body weight in ovariectomized rats. Each point is represented by the mean value SD (n = 7). From the results of FIG. 2, the uterine weight was significantly decreased in the osteoporosis group, but there was a slight increase in the group treated with Goji berry leaves and the estrogen-administered group was significantly increased. Uterine weight loss and uterine atrophy revealed a successful ovarian resection. 3 is a cross-sectional picture of the uterus of the test model. A: the most surgical group, OVX: ovarian isolated osteoporosis control rats, C, D and E: after each ovarian extraction, wolfberry, wolfberry leaves and estradiol group. Hematoxylin and eosin stained sections. The photo is shown at the original magnification x 20. Figure 3 is extracted from the uterine tissue of the rat and fixed with 4% paraformaldehyde for 24 hours, and then embedded in paraffin and the tissue was sliced to a thickness of 5 ㎛ with a microtome. After attaching the sliced tissue on the slide glass, remove the paraffin from xylene and soak it for 5 minutes in order of decreasing concentration such as 100%, 90%, and 80% ethanol, and wash it in running water for 10 minutes. It was. After the slides were dried, HE stained, mounted with Canadian balsam, observed with an optical microscope, and photographed. Results The diameter of the uterine canal was significantly decreased in the osteoporosis and goji berry group compared to the normal group. The diameter of the uterine tube was slightly increased compared to the osteoporosis group, and the estrogen diameter was similar to that of the normal group.
시험예 4: 혈청 오스테오칼신 함량 변화Test Example 4 Change in Serum Osteocalcin Content
혈청을 분리한 후 래트 오스테오칼신 EIA 키트 (Rat Osteocalcin EIA kit , Biomedical Technologies Inc., USA)를 사용하여 오스테오칼신 레벨을 측정하였다. 분리한 혈청을 96-웰 플레이트에 인큐베이션한 후, 세척한 플레이트는 래트 오스테오칼신 펩타이드의 C-말단영역에 대해 높은 특이성을 갖는 2차 항체(second Ab, goat polyclonal)와 반응시켰다. Donkey anti-goat IgG peroxidase로 컨쥬게이션시켰다. TMB (3,3,5.5-tetramethyl benzidine)-기질을 분주하여 반응시킨 후 발색제를 첨가하여 EIA 판독기 (TECAN, 오스트리아)를 이용 흡광도를 측정하였다. 오스테오칼신은 골의 구조에서 칼슘과 단단하게 결합되어 있다. 도 4는 자궁적출한 쥐에서 혈청 오스테오칼신에 미치는 LCF 및 LCL의 효과를 나타내는 도면이다. 바아들은 평균값±SD(n=10)로 나타냈다. P<0.05: 가장 수술군 래트와 비교하였을 때 유의성 차이. 도 4의 혈청 중 오스테오칼신 함량은 구기자 444.6±26.9 ng/ml와 구기자잎 407±18.9 ng/ml로 나타나 골다공증군 107±3.52 ng/ml과 정상군 63.8±5.7 ng/ml에 비하여 유의하게 증가하였다. 에스트로겐 투여군 역시 증가하였다. 이러한 결과는 골다공증시 골아세포에 대한 감소에 따른 파골세포 활성도를 감지할 수 있을 것으로 생각되어지며 본 실험에서 골다공증군이 감소된 소견을 보여 여러 연구자들의 보고와 일치하는 결과를 보였으며 구기자와 구기자잎 투여군에서 현저히 높은 유의성을 보여주었다. After serum separation, osteocalcin levels were measured using a rat Osteocalcin EIA kit (Biomedical Technologies Inc., USA). After incubating the isolated serum in 96-well plates, the washed plates were reacted with a secondary antibody (second Ab, goat polyclonal) with high specificity for the C-terminal region of the rat osteocalcin peptide. Conjugation with Donkey anti-goat IgG peroxidase. TMB (3,3,5.5-tetramethyl benzidine) -substrate was aliquoted and reacted, and then absorbance was measured using an EIA reader (TECAN, Austria) by adding a coloring agent. Osteocalcin is tightly bound to calcium in the structure of the bone. Figure 4 shows the effect of LCF and LCL on serum osteocalcin in uterine isolated mice. Bars are represented as mean ± SD (n = 10). P <0.05: Significance difference compared to the most surgical group rats. The osteocalcin content in the serum of FIG. 4 was 444.6 ± 26.9 ng / ml of goji berry and 407 ± 18.9 ng / ml of goji berry, which was significantly increased compared to 107 ± 3.52 ng / ml of osteoporosis group and 63.8 ± 5.7 ng / ml of normal group. Estrogen-administered groups also increased. These results are thought to be able to detect osteoclast activity according to the decrease in osteoblasts during osteoporosis. The osteoporosis group showed decreased results in this experiment, which is consistent with the reports of several researchers. Significantly high significance was seen in the administration group.
시험예Test Example 5: 알칼린 포스파타아제( 5: alkaline phosphatase ( ALPALP ) 활성도 Activity
알카린 포스파타아제의 활성도 측정은 UV 법에 따라 Daiizhi 시약 (국제주식회사, 일본)을 사용하여 검사장비인 Hirachi 7170A(제일화학)을 활용하여 측정하였다. 알칼린 포소포타아제는 골아세포에서 분비되는 당단백질로 임상에서 흔히 이용되는 골형성표지자이다. ALP는 난소적출 후 활성이 증가된다는 보고가 있다. 도 5는 자궁적출한 쥐에서의 알칼린 포스포타아제 활성에 미치는 LCF 및 LCL의 효과를 나타내는 그라프도이다. 바아들은 평균값±SD(n=7)로 나타냈다. * P<0.05: 가장 수술군 래트와 비교하였을 때 유의성 차이. 본 시험예에 따른 도 5의 결과를 보면 구기자 158±2.2 U/L와 구기잎군 161±2 U/L에서 골다공증군 182±8.1 U/L에 비해 활성도의 감소가 있었다. 이중 구기자 투여군이 에스트로겐 투여군과 근사한 수치 값을 보여주었다. The activity of alkaline phosphatase was measured by using the test equipment Hirachi 7170A (Cheil Chem) using Daiizhi reagent (International Corporation, Japan) according to the UV method. Alkaline posopotase is a glycoprotein secreted by osteoblasts and is a bone marker commonly used in the clinic. ALP has been reported to increase activity after ovarian extraction. 5 is a graph showing the effect of LCF and LCL on alkaline phosphatase activity in uterine isolated mice. Bars are represented as mean ± SD (n = 7). * P <0.05: Significance difference compared to the most surgical group rats. Referring to the results of FIG. 5 according to this test example, there was a decrease in activity in Goji 158 ± 2.2 U / L and Goji leaf group 161 ± 2 U / L compared to osteoporosis group 182 ± 8.1 U / L. Among them, the Goji Wolf administration group showed close to the estrogen group.
시험예 6: 총콜레스테롤, LDL 콜레스테롤, HDL 콜레스테롤, 트리글리세리드 함량Test Example 6: Total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride content
총 콜레스테롤, 트리글리세리드는 Cholesterol-SL Kit, Triglyceride-SL Kit (ELITECH, France)를 사용하여 546 nm, 505 nm 파장에서 각각 측정하였다. 혈액 지질패턴에 미치는 영향은 표 2에 나타냈다. 표 2는 실험 모델에서 총 콜레스테롤, 고밀도 리포프로테인 콜레스테롤, 및 트리글리세리드 함량을 나타낸다. Total cholesterol and triglycerides were measured at 546 nm and 505 nm wavelengths using Cholesterol-SL Kit and Triglyceride-SL Kit (ELITECH, France), respectively. The effect on blood lipid pattern is shown in Table 2. Table 2 shows total cholesterol, high density lipoprotein cholesterol, and triglyceride content in the experimental model.
위 결과에서 알수 있는 바와 같이, 구기자와 구기자잎 투여군이 골다공증군에 비해 총콜레스테롤과 혈액내 중성지방의 농도를 낮추며 HDL 콜레스테롤 수치가 높고, LDL 콜레스테롤은 낮았다. 따라서 본 발명에 따른 구기자 추출물은 혈액 내 중성지방의 축적을 낮추고 항동맥경화 효과를 내포하고 있다고 사료된다. As can be seen from the above results, goji and goji leaf administration group lowered total cholesterol and triglyceride levels in blood, high HDL cholesterol and low LDL cholesterol compared to osteoporosis group. Therefore, goji berry extract according to the present invention is believed to lower the accumulation of triglycerides in the blood and have an anti-arteriosclerosis effect.
시험예 7: 대퇴골의 형태학적 변화Test Example 7: Morphological Changes of the Femur
대퇴골을 분리하여 전고정액 2.5% 글루타르알데하이드(인산염 완충액, pH 7.4)로 2시간 동안 전고정 하였다. 전고정이 끝난 조직은 2주 이상 탈회시킨 후 세로로 절단하고 동일 완충액을 사용 10분 간격으로 3회 세척한 후 1% 오스뮴 테트록시드(Osmium tetroxide)로 2시간 후고정 한 다음 동일 완충액으로 3회 세척하였다. 세척 후 시료들은 상승농도 순의 에탄올로 탈수하여 실온에서 완전히 건조시켰다. 광학현미경으로 관찰, 사진 촬영하였다. 도 6은 난소 적출한지 8주 후의 각 실험 모델의 우측대퇴부의 종단면주사전자 현미경 사진이다. A: 가장 수술군, OVX: 난소적출골다공증 대조군 쥐, C, D 및 E: 각 난소적출후, 구기자, 구기자 잎 및 에스트라디올을 투여한 군. 도 6의 결과에 의하면 해면뼈 잔기 둥의 손실은 정상군에 비하여 골다공증 군에서 가장 현저하였으며, 에스트로겐 투여군이 가장 손실이 미약하였으며 구기자군과 구기자잎 투여군에서도 골다공증군에 비해 미약하였다. 구기자와 구기자잎은 골소실 진행의 감소에 영향을 미침을 확인할 수 있었다.The femur was separated and prefixed with prefixed 2.5% glutaraldehyde (phosphate buffer, pH 7.4) for 2 hours. After pretreatment, the tissues were demineralized for at least two weeks, cut vertically, washed three times with the same buffer every 10 minutes, and then fixed with 2% 1% osmium tetroxide, followed by 3 Washed twice. After washing, the samples were dehydrated with ethanol in increasing order and completely dried at room temperature. Observation and photographing were performed with an optical microscope. Fig. 6 is a longitudinal scanning electron micrograph of the right thigh of each experimental model 8 weeks after ovarian extraction. A: the most surgical group, OVX: ovarian osteoporosis control rats, C, D and E: after each ovarian extraction, wolfberry, wolfberry leaves and estradiol group. According to the results of FIG. 6, the loss of spongy bone residues was most remarkable in the osteoporosis group compared to the normal group, and the estrogen-administered group was the most insignificant. Goji berries and goji leaf influenced the decrease in bone loss progress.
시험예 8: 대퇴골의 탈회표본에서 각 군간 파골세포 및 골아세포의 분포 비교를 위한 조직학적 관찰 Test Example 8: Histological observation for comparison of osteoclasts and osteoblasts in each group in demineralized samples of femur
수술 8주후에 희생시켜 흰쥐의 양측 대퇴골을 골막 분리 후 무게를 측정하였다. 체중 당 대퇴골의 무게에 있어서 골다공증군이 정상군에 비해 약간 낮게 나타났으며 구기자와 구기자잎을 투여한 군, 에스트로겐 투여군 모두 무게변화에 유의한 차이는 없었다. 도 7은 각 실험 모델의 우측 대퇴골 횡단면의 조직학적 변화를 나타내는 사진이다. A: 가장 수술군, B,b: OVX, 난소적출골다공증 대조군 쥐, C,c, D,d 및 E,e: 각 난소적출후, 구기자, 구기자 잎 및 에스트라디올을 투여한 군을 나타낸다. 헤마톡실린 및 에오신 염색 절편, 원본 배율 x40, x200. 도 7은 대퇴골을 분리 후 4% 파라포름알데히드를 사용하여 24시간 고정시킨 2주 이상 탈회한 다음 대퇴골을 횡절단을 하였다. 이후 통상적인 조직제작 과정인 파라핀으로 포매한 후 마이크로톰으로 조직을 6 ㎛두께로 절편하였다. 절편한 조직을 슬라이드 글라스 위에 부착시킨 다음 이를 자일렌에서 파라핀을 제거하고 100%, 90%, 80% 에탄올과 같이 농도가 낮아지는 순으로 5분씩 담구어 함수과정을 거쳐, 흐르는 물에 10분간 세척하였다. 슬라이드 물기를 제거 하여 HE 염색을 한 후 카나다 발삼으로 마운트 하여 광학현미경으로 관찰, 사진 촬영하였다. 도 7에 나타난 것과 같이 정상골 조직에 비해 난소적출술로 골다공증을 유발시킨 쥐의 골조직에서 현저하게 많은 골소실의 소견을 보였다. 구기자와 구기자잎을 투여한 군, 에스트로겐 투여군은 골아세포의 수가 증가하였고 파골세포는 상대적으로 감소하는 분포 현상을 보여주어 골소실의 감소에 영향을 미침이 확인되었다. 이는 골다공증의 여러유형 중 폐경기 이후 골다공증에 대해서 에스트로겐 결핍이 골아세포의 기능적 결여와 관련 있다는 보고와 관련하여 본 실험에서도 조직학적으로 확인되었다. At 8 weeks after surgery, the femoral bones of the rats were measured and their weights were measured after periosteal separation. The osteoporosis group was slightly lower in the weight of the femur per body weight than the normal group, and there were no significant differences in the weight change in the group treated with goji, goji leaf and estrogen. 7 is a photograph showing the histological change of the right femur cross section of each experimental model. A: the most surgical group, B, b: OVX, ovarian osteoporosis control rats, C, c, D, d and E, e: after each ovarian extraction, wolfberry, wolfberry leaves and estradiol groups are shown. Hematoxylin and eosin stained sections, original magnification x40, x200. Figure 7 after the separation of the femur was fixed for 24 hours using 4% paraformaldehyde for 24 hours or more and then the femur was transversely cut. After embedding with paraffin, which is a conventional tissue fabrication process, the tissue was sectioned to a thickness of 6 μm with a microtome. After attaching the sliced tissue on the slide glass, remove the paraffin from xylene and soak it for 5 minutes in order of decreasing concentration such as 100%, 90%, and 80% ethanol, and wash it in running water for 10 minutes. It was. After the slides were dried, HE stained, mounted with Canadian balsam, observed with an optical microscope, and photographed. As shown in FIG. 7, the bone tissues of the mice that caused osteoporosis by ovarian extraction compared to the normal bone tissues showed significantly more bone loss. Goji berry, Goji berry leaves and estrogen-treated groups showed increased osteoblasts and decreased osteoclasts, indicating that bone loss was affected. This was confirmed histologically in this study in relation to the report that estrogen deficiency is related to osteoblast function deficiency in postmenopausal osteoporosis among several types of osteoporosis.
이상 살펴본 바와 같이, 지금까지 설명된 바와 같이 본 발명에 따른 구기자 추출물을 함유하는 고지혈증 및 고콜레스테롤 개선용 기능성 식품은 천연물에서 유래한 것으로 부작용이 없으며 특히, 갱년기의 여성에 있어서 콜레스테롤 및 지질을 현저하게 억제하므로 관련 질환의 개선용 식품 성분 등 다양하게 이용할 수 있다.As described above, as described above, the functional food for improving hyperlipidemia and hypercholesterol containing the goji berry extract according to the present invention is derived from natural products and has no side effects, especially in menopausal women. Since suppression can be used in various ways, such as food ingredients for the improvement of related diseases.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060045576A KR20070112546A (en) | 2006-05-22 | 2006-05-22 | Food composition comprising extracts from lycium chinenses mill |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060045576A KR20070112546A (en) | 2006-05-22 | 2006-05-22 | Food composition comprising extracts from lycium chinenses mill |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070112546A true KR20070112546A (en) | 2007-11-27 |
Family
ID=39090821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020060045576A KR20070112546A (en) | 2006-05-22 | 2006-05-22 | Food composition comprising extracts from lycium chinenses mill |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20070112546A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140050810A1 (en) * | 2012-08-14 | 2014-02-20 | Bionutrigen Co., Ltd. | Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient |
| JP2014510736A (en) * | 2011-04-01 | 2014-05-01 | 桂林商源植物制品有限公司 | Drug composition for suppressing blood sugar, lipemia and body weight |
| WO2017200224A1 (en) * | 2016-05-18 | 2017-11-23 | Olmanfood Co., Ltd. | Composition comprising the combined extract for preventing or treating the abnormal regulation of female hormone and the use thereof |
-
2006
- 2006-05-22 KR KR1020060045576A patent/KR20070112546A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014510736A (en) * | 2011-04-01 | 2014-05-01 | 桂林商源植物制品有限公司 | Drug composition for suppressing blood sugar, lipemia and body weight |
| US20140050810A1 (en) * | 2012-08-14 | 2014-02-20 | Bionutrigen Co., Ltd. | Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient |
| WO2017200224A1 (en) * | 2016-05-18 | 2017-11-23 | Olmanfood Co., Ltd. | Composition comprising the combined extract for preventing or treating the abnormal regulation of female hormone and the use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9649351B2 (en) | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products | |
| KR101412221B1 (en) | Composition of antiobesity containing Lycium chinensis leaf extract powder and betaine as effective ingredients | |
| KR101341648B1 (en) | Composition for preventing and treating varicocele or male infertility comprising anthocyanin extracted from black soybean | |
| KR101523586B1 (en) | Pharmaceutical composition for preventing or treating prostatic hyperplasia and preparation method thereof | |
| US20240245742A1 (en) | Composition Comprising Elderberry Extract as Effective Component for Preventing, Treating, or Alleviating Andropause Syndrome | |
| KR20210122167A (en) | Composition for Preventing, Improving or Treating Postmenopausal Syndrome Comprising Rosa rugosa Thunberg Extract | |
| KR102171001B1 (en) | Method of Aronia extract having improved Anthocyanin content and Anti-obesity effect, and extract of the same | |
| JP2018521003A (en) | Composition for prevention or treatment of benign prostatic hyperplasia containing sykunshi extract | |
| KR102002298B1 (en) | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts | |
| KR20070112546A (en) | Food composition comprising extracts from lycium chinenses mill | |
| US10377902B2 (en) | Crystallized red pigment, method of producing a recrystallized red pigment and a method for improving the appearance of or preventing wrinkles | |
| CN102821773B (en) | Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient | |
| KR101863731B1 (en) | Composition for preventing, improving or treating prostate disease comprising extract of Cardamine scutata as effective component | |
| KR20220046458A (en) | Composition for promoting hair growth and/or inhibiting hair loss | |
| KR101413771B1 (en) | A composition for anti-obesity comprising extract of big cone pine needle | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR102160627B1 (en) | Pharmaceutical composition for preventing or treating bone disease comprising extracts of branches of Hovenia dulcis Thunb | |
| JP2021066673A (en) | Allergic rhinitis symptom inhibitor | |
| JP2007145741A (en) | Ige-capturing agent, and anti-allergic medicine composition, cosmetic composition, food composition, drink composition and feed composition | |
| KR20150105561A (en) | Pharmaceutical composition for preventing or treating bone disease comprising Hovenia dulcis Thunb extract | |
| WO2022100399A1 (en) | Therapeutic application of cell-free fat extract to arthritis | |
| KR100592796B1 (en) | Pharmaceutical Composition for Preventing and Treating Hyperlipidemia Comprising Green Tea Catechins as an Active Ingredient | |
| KR102588771B1 (en) | COMPOSITION COMPRISING EXTRACT Colpomenia sinuosa OR Colpomenia peregrina Sauvageau AS AN ACTIVE INGREDIENT FOR ALLEVIATING OR IMPROVING SYMPTOM BY ESTROGEN REDUCING | |
| KR101203752B1 (en) | Composition comprising Chioneceter japonicur for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases | |
| KR102388984B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING VACCINIUM BRACTEATUM Thunb. EXTRACT FOR Treating and Preventing Benign Prostate Hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |